SCHEMBL773561

SCHEMBL773561

CC(CN1CCCC1)CN1C(=O)c2cc(N)c(N)cc2C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
AHR P35869 1/20 0.36
RECQL P46063 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HRH3 Q9Y5N1 4/20 0.34
LMNA P02545 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CHRM2 P08172 2/20 0.33
ADRA2B P18089 2/20 0.33
DRD3 P35462 2/20 0.33
SIGMAR1 Q99720 2/20 0.33
ALDH1A1 P00352 2/20 0.32
HSD17B10 Q99714 2/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL773541 0.86 MAPT (0.40) MEN1KMT2APOLBMAPTRECQL
SCHEMBL12135915 0.79 HRH3 (0.32) KMT2AHRH3LMNAKDM4EALDH1A1
SCHEMBL768433 0.73 HTR4 (0.48) TERTMEN1KMT2APOLBMAPT
SCHEMBL9407486 0.68 KMT2A (0.55) MEN1KMT2APOLBMAPTHRH3
SCHEMBL438727 0.66 MAPK1 (0.38) MEN1KMT2AMAPTRECQLRAB9A
SCHEMBL9340887 0.65 ALDH1A1 (0.53) KMT2ARAB9ADRD3ALDH1A1MAOB
SCHEMBL16995322 0.64 MAOB (0.49) TERTCHRM2DRD3MAOB
SCHEMBL439776 0.63 ANPEP (0.34) RAB9ALMNAALDH1A1HSD17B10CASP1
SCHEMBL13931 0.62 KMT2A (0.42) MEN1KMT2APOLBMAPTHRH3
SCHEMBL2090291 0.62 KMT2A (0.42) MEN1KMT2APOLBMAPTHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071473-A1 TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS CHEMBRIDGE CORPORATION 2012-03-22 US disclosed
US-20120071473-A1 TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS CHEMBRIDGE CORPORATION 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071473-A1 TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS MALT1, TPMT, TSLP TERT 1263/4885MEN1 1427/4885KMT2A 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.